Sporotrichosis or Endemic Fungal Infection (Histoplasmosis/Blastomycosis)
In a mushroom picker with a large wart and pneumonia refractory to both azithromycin and levofloxacin, the most likely cause is a fungal infection—specifically sporotrichosis (given the cutaneous "wart") or an endemic dimorphic fungus such as histoplasmosis or blastomycosis.
Clinical Reasoning
The key diagnostic clues here are:
- Occupational exposure: Mushroom picker (soil/organic matter exposure)
- Cutaneous lesion: "Large wart" suggests sporotrichoid lymphocutaneous spread or verrucous skin lesion
- Antibiotic failure: No response to macrolide (azithromycin) or fluoroquinolone (levofloxacin)
Why Not Typical Bacterial Pathogens?
The standard CAP guidelines 1, 2 recommend either:
- A respiratory fluoroquinolone (levofloxacin) alone, OR
- A beta-lactam plus macrolide
Both azithromycin and levofloxacin provide excellent coverage for:
- Streptococcus pneumoniae (including MDRSP)
- Haemophilus influenzae
- Atypical pathogens (Mycoplasma, Chlamydophila, Legionella)
Levofloxacin specifically covers Legionella well 1, and while one recent case report 3 suggested possible quinolone superiority over macrolides for severe Legionnaires' disease, failure of BOTH agents makes typical bacterial CAP extremely unlikely.
The Fungal Differential
Sporotrichosis is the leading consideration because:
- Caused by Sporothrix schenckii, a dimorphic fungus found in soil, moss, and decaying vegetation
- Classic occupational exposure in gardeners, farmers, and mushroom workers
- Presents with lymphocutaneous disease (nodular lesions along lymphatic channels that can appear "wart-like")
- Pulmonary sporotrichosis occurs via inhalation and mimics bacterial pneumonia
- Does NOT respond to antibacterial agents
Endemic dimorphic fungi 4 are also critical considerations:
- Histoplasmosis (Histoplasma capsulatum): Found in soil enriched with bird/bat droppings; accounts for up to 30% of CAP in endemic areas
- Blastomycosis (Blastomyces dermatitidis): Associated with soil/organic matter; causes verrucous skin lesions that can mimic warts
- Both cause pneumonia indistinguishable from bacterial CAP and fail to respond to standard antibiotics 4
The combination of pulmonary and cutaneous involvement strongly suggests a systemic dimorphic fungal infection.
Hypersensitivity Pneumonitis—Less Likely
While mushroom workers can develop hypersensitivity pneumonitis from mold spores like Penicillium citrinum 5, this typically presents with:
- Subacute/chronic dyspnea and cough
- Bilateral nodular infiltrates and ground-glass opacities
- Lymphocytic alveolitis on BAL
- No cutaneous lesions
The presence of a "large wart" makes this diagnosis unlikely.
Diagnostic Approach
Immediate steps:
Obtain fungal cultures and histopathology:
- Sputum/BAL for fungal culture and KOH prep
- Skin biopsy of the "wart" with fungal stains (GMS, PAS) and culture
- Look for cigar-shaped yeast (sporotrichosis) or broad-based budding yeast (blastomycosis)
Serum fungal studies:
- Histoplasma urine/serum antigen
- Blastomyces urine antigen
- Serum antibodies for endemic fungi (if available)
Imaging review:
- Cavitary lesions, nodules, or fibronodular infiltrates suggest endemic fungi
- Upper lobe predominance may suggest histoplasmosis or blastomycosis
Treatment Recommendations
Empiric antifungal therapy should be initiated immediately while awaiting cultures given the failure of antibacterial therapy and high mortality risk of untreated fungal pneumonia 1:
- Itraconazole 200 mg PO BID is first-line for mild-moderate pulmonary sporotrichosis, histoplasmosis, and blastomycosis 1
- Amphotericin B is reserved for severe/life-threatening disease or if itraconazole fails 1
For sporotrichosis specifically:
- Itraconazole 200 mg daily for 3-6 months for lymphocutaneous disease
- Higher doses (200 mg BID) for pulmonary involvement
For histoplasmosis/blastomycosis:
- Itraconazole 200 mg TID × 3 days, then 200 mg BID for 6-12 months 1
Critical Pitfalls to Avoid
- Do not continue antibacterial therapy alone—this delays appropriate antifungal treatment and worsens outcomes
- Do not dismiss the cutaneous lesion—it is the key diagnostic clue pointing toward systemic fungal infection
- Do not assume immunocompetence excludes fungal infection—endemic fungi cause disease in immunocompetent hosts 4
- Obtain tissue diagnosis when possible—culture and histopathology are gold standard and guide targeted therapy
The combination of occupational exposure, cutaneous findings, and antibiotic-refractory pneumonia makes fungal infection the diagnosis until proven otherwise.